Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;12(2):131-138.
doi: 10.1212/CPJ.0000000000001161.

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease

Andrew McGarry  1 , Peggy Auinger  1 , Karl D Kieburtz  1 , Amy-Lee Bredlau  1 , Steven M Hersch  1 , H Diana Rosas  1
Affiliations

Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease

Andrew McGarry et al. Neurol Clin Pract. 2022 Apr.

Abstract

Background and objectives: Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial.

Methods: The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E.

Results: We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality).

Discussion: These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials.

Trial registration information: 2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.

PubMed Disclaimer

References

    1. Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24(2):305-311. - PubMed
    1. McGarry A, McDermott MP, Kieburtz K, et al. . Risk factors for suicidality in Huntington disease: an analysis of the 2CARE clinical trial. Neurology. 2019;92(14):e1643-e1651. - PMC - PubMed
    1. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57(3):397-404. - PubMed
    1. McGarry A, McDermott M, Kieburtz K, et al. . A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88(2):152-159. - PMC - PubMed
    1. Hersch SM, Schifitto G, Oakes D, et al. . The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology. 2017;89(6):594-601. - PMC - PubMed

Associated data